🏛️ Verified NIH Record • Updated 2025-12-21
Detection of Early Idiopathic Pulmonary Fibrosis (NCT03457935)
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Temple University
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (5 items).
Location: Temple University — Philadelphia, Pennsylvania
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- HIV
- Hepatitis B
- Hepatitis C
- Pregnant or lactating women inclusion criteria for controls: informed consent \>18 years old; no lung diseases
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Temple University — Philadelphia, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.